Noninvasive quantification of 2-hydroxyglutarate in human gliomas with IDH1 and IDH2 mutations

Cancer Research

Volumn 76, Issue 1, 2016, Pages 43-49

  Emir, Uzay E ^a   Larkin, Sarah J ^a   De Pennington, Nick ^a,b   Voets, Natalie ^a   Plaha, Puneet ^b   Stacey, Richard ^b   Al Qahtani, Khalid ^c   McCullagh, James ^c   Schofield, Christopher J ^c   Clare, Stuart ^a   Jezzard, Peter ^a   Cadoux Hudson, Tom ^b   Ansorge, Olaf ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYGLUTARIC ACID; GLUTAMIC ACID; GLUTATHIONE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; LACTIC ACID; ALPHA-HYDROXYGLUTARATE; GLUTARIC ACID DERIVATIVE; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLIOMA; HUMAN; HUMAN TISSUE; IDH1 GENE; IDH2 GENE; IN VIVO STUDY; MAGNETIC FIELD; MALE; METABOLOMICS; MIDDLE AGED; MUTATIONAL ANALYSIS; NEUROCHEMISTRY; NON INVASIVE PROCEDURE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; BRAIN TUMOR; CASE CONTROL STUDY; ENZYMOLOGY; GENETICS; METABOLISM; MUTATION; PATHOLOGY;

ADULT; BRAIN NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GLIOMA; GLUTARATES; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; MUTATION;

EID: 84958985710     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-0934     Document Type: Article

References (20)

1. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807-12.
2. Ward PS, Lu C, Cross JR, Abdel-Wahab O, Levine RL, Schwartz GK, et al. The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization. J Biol Chem 2013;288:3804-15.
3. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009;462:739-44.
4. Yen KE, Bittinger MA, Su SM, Fantin VR. Cancer-associated IDH mutations: biomarker and therapeutic opportunities. Oncogene 2010;29:6409-17.
5. Choi C, Ganji SK, DeBerardinis RJ, Hatanpaa KJ, Rakheja D, Kovacs Z, et al. 2-hydroxyglutarate detection bymagnetic resonance spectroscopy in IDHmutated patients with gliomas. Nat Med 2012;18:624-9.
6. Andronesi OC, Kim GS, Gerstner E, Batchelor T, Tzika AA, Fantin VR, et al. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med 2012;4:116ra4.
7. Mekle R, Mlynarik V, Gambarota G, Hergt M, Krueger G, Gruetter R. MR spectroscopy of the human brain with enhanced signal intensity at ultrashort echo times on a clinical platform at 3T and 7T. Magn Reson Med 2009;61:1279-85.
8. Shah S, Kellman P, Greiser A, Weale P, Zuehlsdorff S, Jerecic R. Rapid Fieldmap Estimation for Cardiac Shimming. In: Proceedings of the 17th Scientific Meeting, International Society for Magnetic Resonance in Medicine. Honolulu: ISMRM; 2009. Abstract nr 565.
9. Gruetter R, Tkac I. Field mapping without reference scan using asymmetric echo-planar techniques. Magn Reson Med 2000;43:319-23.
10. Teeuwisse WM, Brink WM, Haines KN, Webb AG. Simulations of high permittivity materials for 7 T neuroimaging and evaluation of a new barium titanate-based dielectric. Magn Reson Med 2012;67:912-8.
11. van de Bank BL, Emir UE, Boer VO, van Asten JJ, Maas MC, Wijnen JP, et al. Multi-center reproducibility of neurochemical profiles in the human brain at 7 T. NMR Biomed 2015;28:306-16.
12. Govindaraju V, Young K, Maudsley AA. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed 2000;13: 129-53.
13. Bal D, Gryff-Keller A. 1Hand 13CNMRstudy of 2-hydroxyglutaric acid and its lactone. Magn Reson Chem 2002;40:533-36.
14. Soher BJ, Semanchuk P, Todd D, Steinberg J, Young K. Vespa: integrated applications for RF pulse design, spectral simulation and MRS data analysis. In: Proceedings of the 19th Scientific Meeting, International Society for Magnetic Resonance in Medicine. Quebec, Canada: ISMRM; 2011. Abstract nr 1410.
15. Ortega-Martorell S, Olier I, Julia-Sape M, Arus C. SpectraClassifier 1.0: a user friendly, automated MRS-based classifier-development system. BMC Bioinformatics 2010;11:106.
16. Provencher SW. Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed 2001;14:260-4.
17. Isobe T, Matsumura A, Anno I, Yoshizawa T, Nagatomo Y, Itai Y, et al. Quantification of cerebral metabolites in glioma patients with proton MR spectroscopy using T2 relaxation time correction. Magn Reson Imaging 2002;20:343-9.
18. Oz G, Alger JR, Barker PB, Bartha R, Bizzi A, Boesch C, et al. Clinical proton MR spectroscopy in central nervous system disorders. Radiology 2014; 270:658-79.
19. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1, 010 diffuse gliomas. Acta Neuropathol 2009;118:469-74.
20. Li Y, Srinivasan R, Ratiney H, Lu Y, Chang SM, Nelson SJ. Comparison of T (1) and T(2) metabolite relaxation times in glioma and normal brain at 3T. J Magn Reson Imaging 2008;28:342-50.